tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KLRS Stock Latest News

Positive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments
RatingsPositive Outlook for Kalaris Therapeutics: Buy Rating Affirmed Amid Promising Clinical Developments
6h ago
KLRS
Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)
PremiumThe Fly
Kalaris Therapeutics reports Q3 EPS (64c), consensus (61c)
10h ago
KLRS
Kalaris Therapeutics Appoints New CFO Matthew Gall
PremiumCompany Announcements
Kalaris Therapeutics Appoints New CFO Matthew Gall
9d ago
8K
KLRS
Kalaris Therapeutics appoints Gall as Chief Financial Officer
PremiumThe Fly
Kalaris Therapeutics appoints Gall as Chief Financial Officer
9d ago
KLRS
Kalaris Therapeutics initiated with an Outperform at Citizens JMP
PremiumThe Fly
Kalaris Therapeutics initiated with an Outperform at Citizens JMP
10d ago
KLRS
Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
PremiumRatingsOptimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
2M ago
KLRS
Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103
Premium
The Fly
Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103
2M ago
KLRS
Kalaris Therapeutics initiated with a Strong Buy at Raymond James
Premium
The Fly
Kalaris Therapeutics initiated with a Strong Buy at Raymond James
2M ago
KLRS
Kalaris Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Kalaris Therapeutics Reports Q2 2025 Financial Results
3M ago
KLRS
Kalaris Therapeutics Elects New Directors at Annual Meeting
PremiumCompany Announcements
Kalaris Therapeutics Elects New Directors at Annual Meeting
3M ago
8K
KLRS
Kalaris Therapeutics reports Q2 EPS (61c), consensus (52c)
PremiumThe Fly
Kalaris Therapeutics reports Q2 EPS (61c), consensus (52c)
3M ago
KLRS
Kalaris Therapeutics assumed with a Neutral at Piper Sandler
PremiumThe Fly
Kalaris Therapeutics assumed with a Neutral at Piper Sandler
4M ago
KLRS
Cautious Hold on Kalaris Therapeutics: Awaiting Key Data on TH103’s Potential in Wet AMD
PremiumRatingsCautious Hold on Kalaris Therapeutics: Awaiting Key Data on TH103’s Potential in Wet AMD
4M ago
KLRS
Three new option listings and ten option delistings on July 21st
Premium
The Fly
Three new option listings and ten option delistings on July 21st
4M ago
YI
HES
Kalaris Therapeutics Adjusts Annual Meeting Schedule
Premium
Company Announcements
Kalaris Therapeutics Adjusts Annual Meeting Schedule
5M ago
8K
KLRS
Positive Outlook on Kalaris Therapeutics: Promising Phase 1 Trial and Strong Financial Position Justify Buy Rating
PremiumRatings
Positive Outlook on Kalaris Therapeutics: Promising Phase 1 Trial and Strong Financial Position Justify Buy Rating
6M ago
KLRS
Kalaris Therapeutics Reports Q1 2025 Financials and Progress
PremiumCompany Announcements
Kalaris Therapeutics Reports Q1 2025 Financials and Progress
6M ago
KLRS
Buy Rating for Kalaris Therapeutics: Promising TH103 Development and Strong Financial Position
PremiumRatings
Buy Rating for Kalaris Therapeutics: Promising TH103 Development and Strong Financial Position
6M ago
KLRS
Kalaris Therapeutics reports Q1 EPS ($2.52) vs ($2.60) last year
PremiumThe Fly
Kalaris Therapeutics reports Q1 EPS ($2.52) vs ($2.60) last year
6M ago
KLRS
Buy Rating for Kalaris Therapeutics Driven by Promising Market Potential and Innovative TH103 Therapy
PremiumRatingsBuy Rating for Kalaris Therapeutics Driven by Promising Market Potential and Innovative TH103 Therapy
6M ago
KLRS
Kalaris Therapeutics Amends Executive Employment Agreements
Premium
Company Announcements
Kalaris Therapeutics Amends Executive Employment Agreements
7M ago
8K
KLRS
Kalaris Therapeutic Inc. trading resumes
Premium
The Fly
Kalaris Therapeutic Inc. trading resumes
7M ago
KLRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >